{"nctId":"NCT01001988","briefTitle":"Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers","startDateStruct":{"date":"2009-08-07","type":"ACTUAL"},"conditions":["Encephalitis","Japanese Encephalitis"],"count":596,"armGroups":[{"label":"Study group","type":"EXPERIMENTAL","interventionNames":["Other: Blood sample","Biological: JE-CV administered in Study JEC02"]}],"interventions":[{"name":"Blood sample","otherNames":[]},{"name":"JE-CV administered in Study JEC02","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Provision of Informed Consent Form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations.\n* Participant who was vaccinated with JE-CV in JEC02 trial and had a pre-vaccination blood sample at baseline in JEC02 trial.\n* Participant and parent/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures.\n\nExclusion Criteria :\n\n* Receipt of any JE vaccine other than JE-CV during JEC02 trial and during the period up to inclusion in JEC05 trial.\n* Planned participation in another clinical trial up to the first year of the follow-up in the present trial.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"3 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV","description":"Seroprotection was defined as the proportion of participants with Japanese encephalitis virus neutralizing antibody titers â‰¥10 1/dil as measured by a JE 50% plaque reduction neutralization test (PRNT50).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titers of Japanese Encephalitis Virus Antibodies Following a Single Dose of a JE-CV","description":"Geometric mean titers of Japanese encephalitis virus antibodies were assessed using the PRNT50 test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":591},"commonTop":[]}}}